Fig. 3
POSTN knockdown suppressed the malignant characteristics of glioblastoma cell lines. A, Immunofluorescence images illustrating U87 cell transduction efficiency with lentiviral shPOSTN#1, shPOSTN#2, and control (shNT). B, Western blot analysis of POSTN expression in U87 cells transfected with shPOSTN lentivirus or control, using GAPDH as the reference control. C, qRT-PCR assays of POSTN mRNA levels in U87 cells transfected with shPOSTN lentivirus or control (****P < 0.0001, one-way ANOVA followed by Dunnett’s post-test). D, EDU staining assay for measuring the proliferation of U87 cells transfected with shPOSTN lentivirus or control. Microscopic counts of EDU-positive cells demonstrated proliferation capacity (***P < 0.001, one-way ANOVA followed by Dunnett’s post-test). E, In vitro proliferation assay evaluating the proliferation of U87 cells transfected with shPOSTN lentivirus or control (***P < 0.001, one-way ANOVA followed by Dunnett’s post-test). F, Wound healing assays of U87 cells transfected with shPOSTN lentivirus or control at baseline (top) and day 3 (bottom). The cell migration distance was significantly reduced in the shPOSTN treatment group compared to the control group (*P < 0.05, one-way ANOVA followed by Dunnett’s post-test). G, Cell invasion assays of U87 cells transfected with shPOSTN lentivirus or control (*P < 0.05, one-way ANOVA followed by Dunnett’s post-test). H, Colony formation assays of U87 cells transfected with shPOSTN lentivirus or control (**P < 0.01, one-way ANOVA followed by Dunnett’s post-test).
